Skip to main content
  • HFSA: Clinical Benefits Tied to Lung Monitoring Persist HF rehospitalization, deaths remain reduced up to 4.5 years

    ORLANDO — The clinical benefits observed with using a monitoring device for lung congestion were maintained in the longer run, according to results from the IMPEDANCE-HF trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details